Time to fix healthcare

This is in reference to the article “The future belongs to biologics” (December 27). Kanchana TK makes an empathic case for stepping up investments in biomedical research. She is right about the innovations in medicine but wants government intervention for biologics. She quotes how China has made significant advancements in the same sphere. These are multi-pronged issues and cannot be generalised.

While personalised medicine is the holy grail, cost structures to justify the same are prohibitive. Indian pharma companies have been under cloud for several irregularities in making generics and censures from US-FDA for their good manufacturing practises. They are